Why the study?
The structure of cardiac drug prescriptions by primary care physicians has remained unknown for a long time.
Does rosuvastatin improve lipid and cholesterol levels in primary care patients with lipid metabolism disorders and hypercholesterolemia?
Observational
Does rosuvastatin improve lipid and cholesterol levels in primary care patients with lipid metabolism disorders and hypercholesterolemia?
Answers are grounded in this paper and cite their sources.
The OZIRKA study aims to provide real-world data on the prescription patterns of cardiac drugs and the efficacy of rosuvastatin in primary care.
The structure of prescriptions of cardiac drugs by the primary care physicians has remained unknown for a long time. We decided to use the data of the OZIRKA study, which aimed to investigate the effect of Ozalex (rosuvastatin) on lipid and cholesterol levels in patients with lipid metabolism disorders and hypercholesterolemia, and to assess the structure of prescriptions in real clinical practice, as well as the effectiveness of cardiovascular risk factors monitoring. We sincerely hope that the data we have obtained will optimize the treatment plan for primary care patients, improve their prognosis and survival, and provide the practitioner with evidence of the safety and efficacy of rosuvastatin that can be transferred to routine clinical practice.
No takes yet. Share an insight, caveat, or question.
Torbas et al. (2021) conducted an observational in Lipid metabolism disorders and hypercholesterolemia. Ozalex (rosuvastatin) was evaluated on Lipid and cholesterol levels, structure of prescriptions, and effectiveness of cardiovascular risk factors monitoring.
Synapse has enriched 10 related papers. Consider them for comparative context: